Diabetologia:一种有前景的2型糖尿病治疗方法?

2018-04-12 MedSci MedSci原创

目前正在出现一类称为生物电子药物的新型治疗方法,该方法的目标是针对个体神经纤维或病理状态下的特定脑回路修复失去的功能并恢复健康的平衡。近日,国际杂志 《Diabetologia》上在线发表一项一种潜在的2型糖尿病治疗方法的研究,主要内容是关于生物电子调节大鼠颈动脉窦神经活动。 已有研究显示颈动脉窦神经(CSN)去神经支配可改善胰岛素抵抗和葡萄糖不耐受大鼠的葡萄糖体内平衡;然而,手术的这些积

目前正在出现一类称为生物电子药物的新型治疗方法,该方法的目标是针对个体神经纤维或病理状态下的特定脑回路修复失去的功能并恢复健康的平衡。近日,国际杂志 《Diabetologia》上在线发表一项一种潜在的2型糖尿病治疗方法的研究,主要内容是关于生物电子调节大鼠颈动脉窦神经活动。 已有研究显示颈动脉窦神经(CSN)去神经支配可改善胰岛素抵抗和葡萄糖不耐受大鼠的葡萄糖体内平衡;然而,手术的这些积极效果似乎会随着时间的推移减弱,并且其效果受到与化学感觉功能的永久丧失相关的严重不良反应严重影响。在这里,研究人员描述了一种新型千赫频率交流电(KHFAC)调节的生物电子应用,以抑制啮齿动物CSN内的神经信号。 在14周内给大鼠喂食或高脂肪/高蔗糖(HFHSu)饮食(60%富脂饮食加35%蔗糖饮用水)。神经接口双侧植入CSNs并附加到外部脉冲发生器。随后将大鼠随机分配至KHFAC或未调制组。通过呼吸和心脏对缺氧(10%O 2+90%N 2)反应来定义KHFAC调制变量。通过ITT定期评估胰岛素敏感性,并通过OGTT评估葡萄糖耐量。 研究发现,应用超过9周的CSN的KHFAC调节恢复了2型糖尿病大鼠模型

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760639, encodeId=2ad51e60639ef, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 30 19:15:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989980, encodeId=b940198998062, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Apr 21 01:15:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080910, encodeId=f7dd2080910d5, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Mon Dec 31 23:15:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638556, encodeId=345c16385566c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 20 09:15:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306159, encodeId=7ce2306159c3, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/6f2d63c799d68129300901eb0e962dd4.jpg, createdBy=ddf12178538, createdName=小贝熊, createdTime=Mon Apr 16 00:06:55 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399243, encodeId=d1af13992434d, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Apr 14 06:15:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760639, encodeId=2ad51e60639ef, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 30 19:15:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989980, encodeId=b940198998062, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Apr 21 01:15:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080910, encodeId=f7dd2080910d5, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Mon Dec 31 23:15:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638556, encodeId=345c16385566c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 20 09:15:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306159, encodeId=7ce2306159c3, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/6f2d63c799d68129300901eb0e962dd4.jpg, createdBy=ddf12178538, createdName=小贝熊, createdTime=Mon Apr 16 00:06:55 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399243, encodeId=d1af13992434d, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Apr 14 06:15:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760639, encodeId=2ad51e60639ef, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 30 19:15:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989980, encodeId=b940198998062, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Apr 21 01:15:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080910, encodeId=f7dd2080910d5, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Mon Dec 31 23:15:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638556, encodeId=345c16385566c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 20 09:15:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306159, encodeId=7ce2306159c3, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/6f2d63c799d68129300901eb0e962dd4.jpg, createdBy=ddf12178538, createdName=小贝熊, createdTime=Mon Apr 16 00:06:55 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399243, encodeId=d1af13992434d, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Apr 14 06:15:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760639, encodeId=2ad51e60639ef, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 30 19:15:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989980, encodeId=b940198998062, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Apr 21 01:15:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080910, encodeId=f7dd2080910d5, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Mon Dec 31 23:15:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638556, encodeId=345c16385566c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 20 09:15:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306159, encodeId=7ce2306159c3, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/6f2d63c799d68129300901eb0e962dd4.jpg, createdBy=ddf12178538, createdName=小贝熊, createdTime=Mon Apr 16 00:06:55 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399243, encodeId=d1af13992434d, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Apr 14 06:15:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1760639, encodeId=2ad51e60639ef, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 30 19:15:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989980, encodeId=b940198998062, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Apr 21 01:15:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080910, encodeId=f7dd2080910d5, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Mon Dec 31 23:15:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638556, encodeId=345c16385566c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 20 09:15:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306159, encodeId=7ce2306159c3, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/6f2d63c799d68129300901eb0e962dd4.jpg, createdBy=ddf12178538, createdName=小贝熊, createdTime=Mon Apr 16 00:06:55 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399243, encodeId=d1af13992434d, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Apr 14 06:15:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]
    2018-04-16 小贝熊

    学习学习学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1760639, encodeId=2ad51e60639ef, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Aug 30 19:15:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989980, encodeId=b940198998062, content=<a href='/topic/show?id=3207e6735ae' target=_blank style='color:#2F92EE;'>#糖尿病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76735, encryptionId=3207e6735ae, topicName=糖尿病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sat Apr 21 01:15:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080910, encodeId=f7dd2080910d5, content=<a href='/topic/show?id=6d0260588eb' target=_blank style='color:#2F92EE;'>#有前景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60588, encryptionId=6d0260588eb, topicName=有前景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Mon Dec 31 23:15:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638556, encodeId=345c16385566c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jul 20 09:15:00 CST 2018, time=2018-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306159, encodeId=7ce2306159c3, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/6f2d63c799d68129300901eb0e962dd4.jpg, createdBy=ddf12178538, createdName=小贝熊, createdTime=Mon Apr 16 00:06:55 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399243, encodeId=d1af13992434d, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Apr 14 06:15:00 CST 2018, time=2018-04-14, status=1, ipAttribution=)]

相关资讯

Diabetes Care:胶原VI形成与2型糖尿病合并微量白蛋白尿患者的全因死亡有关!

由此可见,COLⅥ形成过程中产生的s-PRO-C6可预测2型糖尿病合并微量白蛋白尿患者的心血管事件、全因死亡以及疾病进展。

Diabetologia:心脏代谢危险因素与2型糖尿病诊断年龄相关的短期进展

近日,国际杂志 《Diabetologia》上在线发表一项关于来自瑞典国家糖尿病登记处的100,606人的纵向观察的研究,研究心脏代谢危险因素与2型糖尿病诊断年龄相关的短期进展。 相对于迟发型疾病,对早发型2型糖尿病的过早死亡和与之相关的原因尚不清楚。研究人员评估了2型糖尿病诊断的临床特征以及诊断后最初几年与诊断年龄相关的心脏代谢危险因素的关系。 研究队列由2002年至2012年在瑞典

Hepatol Res:胰岛素耐受增加了非酒精性肝病患者2型糖尿病患病风险

NASH患者有潜在葡萄糖耐受不良的风险。在NAFLD患者中,胰岛素抵抗是T2DM发病的最重要的危险因素。NAFLD患者需要适当的胰岛素抵抗治疗,以预防T2DM的发展。

Diabetologia:现实中2型糖尿病人群的血糖恶化率如何?

javascript:void(0);/*1523345563770*/糖尿病在诊断后的发展存在很大的差异。进展模式主要集中在“时间依赖衰竭”方法上,确定“衰竭系数”有很多优点。研究人员使用大型现实队列得出2型糖尿病的血糖恶化率,旨在调查与血糖恶化速度快和缓慢相关的临床,生化,药理学和免疫学变量。近日,国际杂志 《Diabetologia》上在线发表一项关于现实中2型糖尿病人群的血糖恶化率的研究。

营养不良可能是造成2型糖尿病的重要原因

犹他州西南部的研究人员报告说,居住在美国等发达国家的南亚人对营养不良的饮食选择是导致2型糖尿病发病率上升的主要原因。

NEJM:童年到成年早期超重的变化与2型糖尿病风险!

由此可见,7岁时儿童超重与成人2型糖尿病风险增加有关。